November 17, 2022
1 thousand watches
Parsegov reports no relevant financial information.
Healio spoke to Bryn H. Parsegov, PA-C, on a presentation exploring the timing, as well as the impact, of diagnosis of myeloproliferative neoplasms.
The presentation was carried out by His Hasselbalchdoctor, doctor, clinical researcher at Hróskeldal Hospital in Copenhagen, at the 14th International Congress on Myeloproliferative Tumors.
“What I really took away from his presentation was just all the ways that the inflammatory background of these diseases can affect our patients,” said Parsegov, MD, assistant professor of hematology and hematological malignancies at the University of Utah’s Huntsman Cancer Institute. , said.
She noted that the field of myeloproliferative neoplasms is highly specialized, but emphasized “not forgetting the big picture” when treating patients.
“In his presentation, he equated an inflammatory environment to being similar to a type II diabetes environment, which we generally understand can be very, very harmful,” Parsegov said. “Looking at it with a broader lens, in that way, will help me provide better care to my patients.”
- Hasselbalch H. A paradigm shift in the diagnosis and treatment of MPN – sooner rather than later? Presented at: 14th International Congress on Myeloproliferative Neoplasms; October 27-28, 2022; Brooklyn, New York.